Gram-positive pathogens are the leading cause of hospital-acquired infections. Our main research interest is the development of novel strategies against multiresistant staphylococci and enterococci and application of in-vivo models to study virulence mechanism and efficacy of novel antibacterials.
In particular, we have a wide experience in infection models, evaluation of antibacterials, determining the mode of action of antibacterial compounds, and interaction of Staphylococcus aureus with the host immune system. Current projects particularly focus on novel targets for antibiotics, regulation of resistance and virulence, and gene expression analysis during infection.
Hung S, Dreher L, Diessner J, Schwarz, S, Ohlsen K*, Hertlein T* (2022)
MRSA infection in the thigh muscle leads to systemic disease, strong Inflammation, and loss of human monocytes in humanized mice
Frontiers in Immunology 13:892053. *joined senior authors
Ibrahim ES, Ohlsen K (2022)
The Old Yellow Enzyme OfrA Fosters Staphylococcus aureus Survival via Affecting Thiol-Dependent Redox Homeostasis
Frontiers in Microbiology 13:888140
Umstätter F, Domhan C, Hertlein T, Ohlsen K, Mühlberg E, Kleist C, Zimmermann S, Beijer B, Klika KD, Haberkorn U, Mier W, Uhl P (2020)
Vancomycin resistance is overcome by conjugation of polycationic peptides
Angewandte Chemie International Edition 59(23):8823
Seethaler M, Hertlein T, Wecklein B, Ymeraj A, Ohlsen K, Lalk M, Hilgeroth A (2019)
Novel small-molecule antibacterials against Gram-positive pathogens of Staphylococcus and Enterococcus species.
Antibiotics 8(4): E210
Fan SH, Ebner P, Reichert S, Hertlein T, Zabel S, Lankapalli AK, Nieselt K, Ohlsen K, Götz F (2019)
MpsAB is important for Staphylococcus aureus virulence and growth at atmospheric CO2 levels
Nature Communications 10(1):3627